Morgan Stanley Apellis Pharmaceuticals, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,389,785 shares of APLS stock, worth $113 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,389,785
Previous 2,118,897
59.98%
Holding current value
$113 Million
Previous $81.3 Million
20.28%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$517 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$395 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$369 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$326 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$192 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.65B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...